- 1 Developmental and genetic regulation of the human cortex transcriptome in schizophrenia
- 2
- 3 Andrew E Jaffe^{1,2,3,4,#}, Richard E Straub¹, Joo Heon Shin¹, Ran Tao¹, Yuan Gao¹, Leonardo
- 4 Collado Torres^{1,3,4}, Tony Kam-Thong⁵, Hualin S Xi⁶, Jie Quan⁶, Qiang Chen¹, Carlo
- 5 Colantuoni^{1,7,8}, Bill Ulrich¹, Brady J. Maher^{1,9}, Amy Deep-Soboslay¹, The BrainSeq Consortium,
- 6 Alan Cross¹⁰, Nicholas J. Brandon¹⁰, Jeffrey T Leek^{3,4}, Thomas M. Hyde^{1,7,9}, Joel E. Kleinman^{1,7},
- 7 Daniel R Weinberger^{1,8,9,11,&}
- Lieber Institute for Brain Development, Johns Hopkins Medical Campus, Baltimore, MD
 21205, USA
- Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore,
 MD, 21205, USA
- Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore,
 MD, 21205, USA
- 14 4. Center for Computational Biology, Johns Hopkins University, Baltimore MD 21205 USA
- Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche
 Innovation Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel,
 Switzerland
- 18 6. Computational Sciences, Pfizer Inc, Cambridge, MA 02140
- 19 7. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21205, USA
- B. Department of Neuroscience, Johns Hopkins School of Medicine, Baltimore, MD 21205,
 USA
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine,
 Baltimore, MD 21205, USA
- 10. AstraZeneca Neuroscience iMed, IMED Biotech Unit, Cambridge, MA, 02139 USA
- 11. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins School of Medicine,
 Baltimore, MD 21205, USA
- 27 # <u>andrew.jaffe@libd.org</u> (co-corresponding)
- 28 & <u>drweinberger@libd.org</u> (co-corresponding)
- 29

30

31 Summary:

32 GWAS have identified over 108 loci that confer risk for schizophrenia, but risk mechanisms for 33 individual loci are largely unknown. Using developmental, genetic, and illness-based RNA 34 sequencing expression analysis, we characterized the human brain transcriptome around these loci and found enrichment for developmentally regulated genes with novel examples of shifting 35 isoform usage across pre- and post-natal life. Within patients and controls, we implemented a 36 novel algorithm for RNA quality adjustment, and identified 237 genes significantly associated 37 with diagnosis that replicated in an independent case-control dataset. These genes implicated 38 synaptic processes and were strongly regulated in early development ($p < 10^{-20}$). Lastly, we 39 found 42.5% of risk variants associate with nearby genes and diverse transcript features that 40 converge on developmental regulation and subsequent dysregulation in illness and 34 loci show 41 convergent directionality with illness association implicating specific causative transcripts. These 42 data offer new targets for modeling schizophrenia risk in cellular systems. 43

44

45

46 Key Words: schizophrenia, functional genomics, RNA sequencing, human postmortem brain,

47 differential expression analysis, RNA degradation

48

49 Introduction:

50 Schizophrenia (SCZD) is a prevalent neuropsychiatric disorder with a combination of 51 genetic and environmental risk factors. Research over the last several decades has suggested that SZCD is a neurodevelopmental disorder arising through altered connectivity and plasticity 52 in relevant neural circuits. However, discovering the causative mechanisms of these putatively 53 developmental deficits has been very challenging¹. The most consistent evidence of etiologic 54 mechanisms related to SCZD has come from a recent genome-wide association study (GWAS) 55 in which over a hundred independent single nucleotide polymorphisms (SNPs) were identified 56 having an allele frequency difference between patients with schizophrenia and unaffected 57 58 controls². While these findings have identified regions in the genome harboring genetic risk variants, almost all of the associated SNPs are non-coding, located in intronic or intergenic 59 sequence, and hypothesized to have some role in regulating expression³. However, the exact 60 gene(s) and transcript(s) potentially regulated by risk-associated genetic variation are uncertain, 61 62 as most of these genomic regions contain multiple genes. In principle, the effects of non-coding genetic variation, by whatever mechanisms (e.g. promoter, enhancer, splicing, noncoding RNA, 63 epigenetics, etc), should be observed in the transcriptome. Therefore, to better understand how 64 these regions of genetic risk and their underlying genotypes may confer risk of schizophrenia 65 and to better characterize the molecular biology of the disease state, we sequenced the polyA+ 66 67 transcriptomes from the prefrontal cortex of 495 individuals with ages across the lifespan, ranging from the second trimester of fetal life to 85 years of age (see Table S1), including 175 68

69 patients with schizophrenia (see Figure S1).

70 Here we identify novel expression associations with genetic risk and with illness state 71 and explore developmentally regulated features, including a subset of genes with previously 72 uncharacterized isoform shifts in expression patterns across the fetal-postnatal developmental 73 transition. We further identify many more expression quantitative loci (eQTLs) in schizophrenia 74 risk regions then previously observed by surveying the full spectrum of associated expression 75 features to generate potential molecular mechanisms underlying genetic risk. We also explore differential gene expression associated with the state of illness in a comparison of the 76 postmortem brains of patients with schizophrenia with non-psychiatric controls. By 77 incorporating a novel, experiment-based algorithm to account for RNA quality differences which 78 have not been adequately controlled in earlier studies, we report a high degree of replication 79 across independent case-control gene expression datasets^{4,5}. By combining genetic risk at the 80 population-level with eQTLs and case-control differences, we identify putative human frontal 81 cortex mechanisms underlying risk for schizophrenia and replicable molecular features of the 82 83 illness state.

84

85 Results

We performed deep polyA+ RNA-sequencing of 495 individuals, ranging in age from the second trimester of fetal life to 85 years old (see Table S1), including 175 patients with 88 schizophrenia (see Figure S1). We quantified expression across multiple transcript features,

including: annotated 1) genes and 2) exons, 3) annotation-guided transcripts⁴ as well as

alignment-based 4) exon-exon splice junctions⁵ and 5) expressed regions $(ERs)^6$. These last

two expression features were selected to reduce reliance on the potentially incomplete

⁹² annotation of the brain transcriptome⁷ (Results S1). We find a large number of moderately

93 expressed and previously unannotated splice junctions that tag potential transcripts with

94 alternative exonic boundaries or exon skipping (Figure S2), 95% of which are also found in

95 other large RNA-seq datasets, including a subset that were brain-specific (Table 1). Similarly,

we find that only 56.1% of ERs were annotated to strictly exonic sequence – many ERs
 annotated to strictly intronic (22.3%) or intergenic (8.5%) sequence, or were transcribed beyond

existing annotation (e.g. extended UTRs, extended exonic sequence).

99

100 Developmental regulation of transcription and shifting isoform usage

Characterizing expression changes in unaffected individuals, particularly across brain 101 development beginning with prenatal life, has previously offered disease-relevant insights into 102 particular genomic loci⁸⁻¹². Specifically, we and others ^{7,13,14} have shown that genomic risk loci 103 associated with neurodevelopmental disorders including schizophrenia are enriched for 104 105 transcript features showing differential expression between fetal and postnatal brains. Here too, among the 320 control samples, the strongest component of expression change corresponded 106 107 to large expression changes in the contrast of pre-natal and early postnatal life, in line with previous data ⁷ (Figure 1A). We further defined a developmental regulation statistic for each 108 expressed feature using a generalized additive model (see Methods) and found widespread 109 developmental regulation of these expressed features (Results S2, Table S3, Figure S3), 110 including of previously unannotated sequence (Table S4). Motivated in part by previous reports 111 of preferential fetal isoform use among schizophrenia candidate risk genes^{10,11} (e.g predominant 112 113 fetal versus predominant postnatal isoforms), we next formally identified the subset of genes showing alternative isoform expression patterns across fetal and postnatal life using those 114 exons, junctions, transcripts, and ERs that meet the statistical criteria for developmental 115 regulation (, i.e. those genes with at least one developmentally changing feature, see Methods). 116 There were 9,161 Ensembl genes (28% of the set of developmentally regulated genes) with 117 both positive and negative expression features having genome-wide significant correlations to 118 age (each with p_{bonf}<0.05, Figure 1B, Table S5, Figure S4). In other words, these represent 119 120 alternate transcript isoforms of the same gene that show opposite patterns of expression across the prenatal-postnatal transition. 121

We performed gene set analyses of those genes with shifting isoform usage compared to the larger set of genes with at least one developmentally regulated feature but without shifting isoform usage to identify more specific biological functions of this unique form of developmental regulation (Table S6). The set of developmentally shifting isoforms was relatively enriched for localization, catalytic activity, signaling-related processes, including synaptic transmission and cell communication, and neuronal development, among many others. Interestingly, genes identified with shifting isoforms across development based exclusively on junction counts were

enriched for both dopaminergic (FDR= 5.11×10^{-7}) and glutamatergic (FDR= 4.02×10^{-4}) synapse

130 KEGG pathways (Figure 1C), the two neurotransmitter systems most prominently implicated in

131 schizophrenia pathogenesis and treatment.

132

133 Schizophrenia risk is associated with shifting isoform usage across brain development

Based on the KEGG analysis, we hypothesized that the genes with developmentally 134 regulated isoform shifts may relate to risk for schizophrenia. Indeed, genes within the SZCD 135 136 GWAS risk loci were more likely to harbor these isoform shifts occurring in the fetal-postnatal 137 developmental transition compared with the rest of the expressed transcriptome (Figure 2D). For example, genes with developmental isoform shifts identified by exon and junction counts 138 were 62% ($p=4.1\times10^{-5}$) and 69% ($p=5.6\times10^{-7}$) more likely to lie within the PGC2 risk regions 139 (with permutation-based p = 0.048 and 0.02 respectively, see Methods) than developmentally 140 141 regulated genes without isoforms shifts (Table S7). These results further underscore the role of changes in the regulation of transcription and splicing in early brain development in 142 143 schizophrenia risk.

144

145 Expression associations with chronic schizophrenia illness

We next explored the expression landscape of the prefrontal cortex of the schizophrenia 146 147 illness state and its potential link with developmental regulation and genetic risk. We performed differential expression modeling using 351 higher quality adult samples (196 controls, 155 148 cases), and found extensive bias by RNA degradation within both univariate analysis (where 149 12,686 genes were differentially expressed at FDR<5%) and even after adjusting for measured 150 levels of RNA guality typical of all prior studies (Figure S5). We therefore implemented a 151 152 statistical framework based on an independent molecular degradation experiment (see 153 Methods, Results S3), called "quality surrogate variable analysis" (qSVA, see Methods)¹⁵. We further utilized replication RNA-seg data from the CommonMind Consortium (CMC) dataset. 154 155 using a subset of age range-matched 159 schizophrenia patients and 172 controls. Interestingly, adjusting for observed factors related to RNA guality that characterize all earlier 156 157 studies of gene expression in schizophrenic brain, the proportion of genes with differentially 158 expressed features at genome wide significant FDR < 5% that replicate (with directionality and marginal significance) in the CMC dataset was very small (only 11.0%, 244/2,215, Figure S6). In 159 contrast, using our new statistical qSVA approach, 40.1% of differentially expressed genes at 160 161 FDR < 5% (N=75/183) replicate in the CMC dataset. At genome-wide significant FDR<10% 162 (see Methods), we identified 237 genes with 556 DE features that replicated in the CMC dataset 163 (33.6% gene-level replication rate, Table S8, Table S9).

164 The differences in expression levels between cases and controls of these DE features 165 were generally small in both our discovery and the replication datasets (Figure 2A, Figure S7), 166 perhaps a direct result of the clinical and molecular heterogeneity of this disorder ^{13,16}. Gene 167 ontology analysis implicated transporter- and channel-related signaling as significantly

consistently downregulated in patients compared to controls across genes annotated in all three 168 expression summarizations (Figure 2B, Table S10). These results suggested decreased 169 signaling in patients with schizophrenia, but could raise the possibility that these replicated 170 expression differences between patients and controls relate to the epiphenomena of illness. 171 such as treatment with antipsychotics which affect signaling in the brain¹⁴, as the majority of 172 patients were on anti-psychotics at the time of death (64%, Table S1). Only two genes (KLC1 173 174 and PPP2R3A) in the 108 significant schizophrenia GWAS loci were significantly differentially 175 expressed. However, in an exploratory analysis, we found that overall the differential expression 176 statistics within the loci were significantly different than those features outside the loci (Results S4, Figure S8, Table S11). We also investigated the relationships between transcription and 177 genomic risk for schizophrenia using genome wide Risk Profile Scores (RPS) from each subject 178 calculated as previously described² (see Methods). Using the subset of 209 Caucasian 179 samples, we largely found a lack of association between RPS and expression of individual 180 expression features. We further found a lack of enrichment of RPS on expression comparing the 181 differentially expressed and replicated case-control features to the rest of the transcriptome, as 182 183 well as lack of directionally consistency between RPS- and diagnosis-associated statistics 184 among expressed features (Table S12). These results further suggest that the significant casecontrol expression differences show little overlap with genetic risk for the disorder. 185

In an earlier study of the epigenetic landscape of frontal cortex of patients with 186 schizophrenia, we showed that DNA methylation levels in patients were closer to fetal 187 methylation levels than to those of adult control samples¹⁷. Here we tested for analogous effects 188 in the RNA-seq data related to the illness state. Every significant gene with differentially 189 190 expressed features in the adult case-control analysis and replicated in the independent dataset 191 showed evidence for developmental regulation across at least two expression feature types. We further found that the expression features normally more highly expressed in postnatal life 192 tended to be more lowly expressed in patients compared to controls (max: $p=3.24 \times 10^{-11}$, min: 193 p=1.05x10⁻⁷⁰, Figure 2C) and features more highly expressed in fetal life tended to be more 194 highly expressed in patients with schizophrenia compared to controls regardless of 195 summarization type (max: $p=6.86 \times 10^{-33}$, min: $p < 10^{-100}$, Figure 2D). Analogous analyses for 196 197 developmental regulation of schizophrenia-associated features without adjusting for the RNA 198 quality qSVs were significant in the opposite directions, namely that schizophrenia-associated 199 changes were further from, rather than closer to, fetal expression levels, which would be 200 predicted as an artifact of residual RNA quality confounding (as the quality of the samples rank as fetal > adult control > adult SZ, see Table S1). These results further converge on a role for 201 genes changing during brain development and maturation in schizophrenia, specifically that 202 both DNA methylation and expression levels in adult patients appear to reflect levels in the 203 developing brain more strongly than do those of unaffected individuals. These results also 204 205 underscore the risk of spurious findings based on uncorrected RNA quality confounding.

206

207 Clinical enrichment of eQTL associations for schizophrenia

In order to elucidate the RNA features associated with schizophrenia risk variants 208 209 themselves, rather than LD regions, we first performed a genome-wide *cis* (<500kb) expression quantitative trait loci (eQTL) analysis within the 412 post-adolescent subjects (see Methods). 210 We then replicated SNP-feature eQTL pairs in two independent datasets (CMC and GTEx) to 211 form a significant and replicated set of high-confidence eQTLs ("core eQTLs") to interrogate for 212 clinical risk. Overall, we confirm widespread genetic control of expression in human brain 213 (Figure 3A, Table S13, Table S14) which can be accessed by the research community via a 214 215 user friendly browser at eqtl.brainseq.org. The majority of these core eQTLs were largely gene-216 specific, consistent across both interrogated races (Results S5, Figure 3B), very proximal to the TSS of genes (Figure 3C), and expression of the majority of genes was associated with more 217 than 1 LD-independent SNP. We further found the largest effect sizes on average for the 218 junction and ER eQTLs (Figure 3D), and interestingly a large proportion of these eQTLs 219 corresponded to unannotated transcriptional activity. While the majority of genes with features 220 as eQTLs have multiple possible Ensembl transcript isoforms, 67.0% of exon eQTLs and 31.1% 221 of junction eQTLs were specific to a single Ensembl transcript when multiple transcripts existed 222 223 for a given gene. Together these eQTL results, based on analyses across multiple feature 224 summarizations from RNA sequencing data, demonstrate more widespread genetic regulation of expression than previously reported, including extensive transcript specificity and regulation 225 226 of unannotated sequence in the human brain. These observations offer novel insights into cis mechanisms of common variation in brain. 227

228 We next explored the landscape of eQTLs associated with genetic risk using the set of 229 core eQTLs among the PGC2-significant risk SNPs. There were 46 (42.5%) risk SNPs significantly associated with expression levels of 764 nearby features at FDR < 1% significance 230 231 (Table S15, of the 108/128 PGC2 "index" SNPs that were present in our data). This proportion of SNPs was highly significant ($p=4.6 \times 10^{-9}$) relative to the 19.7% of all tested common variants 232 with eQTL signal. These risk eQTL features mapped back to 134 Ensembl genes (and 116 gene 233 symbols). Interestingly, many of these adult-identified eQTLs show similar genetic regulation in 234 fetal brain, analogous to observations made among methylation quantitative trait loci (meQTLs) 235 at these risk SNPs^{17,18}. In addition, the majority of these genetic risk-associated expression 236 237 features were developmentally regulated across the lifespan in our control samples (N=528, 238 69.1%), suggesting that different developmental time periods may have different magnitudes of 239 eQTL effects among these risk-associated expressed features. Even more strikingly, 57 genes (42.5%) having risk SNP eQTLs had shifting isoform usage across pre- and post-natal life, a 240 highly enriched proportion relative to all expressed genes (9,205/43,046 genes with isoform 241 shifts, OR=2.73, p=4.21x10⁻⁹), further highlighting developmental relevance for schizophrenia 242 genetic risk. 243

244

245 Identifying risk transcripts through clinical and molecular convergence

In principle, transcripts with convergence of directionality of association with both genetic
 risk and with clinical illness are especially attractive as putative molecular mechanisms of illness
 and as candidates for designing pathogenic models. We therefore used allele information and

the corresponding effect estimates in the GWAS (odds ratio) and eQTL analyses (change in 249 250 expression per allele copy) to test which of the expressed features that differentiated patients 251 and controls were directionally consistent with the allelic directionality of genetic risk. In other 252 words, if a given allele at a risk associated SNP is associated with increased expression of a nearby feature via the eQTL analysis, we tested whether expression of the same feature was 253 254 more likely to be higher in patients compared to controls (Results S6, Figure 4A). Indeed, we 255 found two-fold enrichment of this directional consistency between the GWAS, case-control, and FDR-significant eQTLs (p=4.2x10⁻⁶). In order to reduce the chances of off-target eQTLs being 256 257 driven by correlated expression features, we lastly retained SNP-feature associations that were at least half as significant on the log₁₀ scale as the best eQTL for each GWAS index SNP (e.g. if 258 the best eQTL association for a risk SNP was $p < 1x10^{-10}$, then eQTLs with $p > 1x10^{-5}$ were 259 260 excluded).

261 This approach resulted in core eQTL signal across 34 GWAS loci with convergence of 262 allele and illness state expression directionality (encompassing 59 genes across 231 features, Table S16). These are transcript features and genes that show consistent directionality of 263 association of genetic risk alleles and of illness state, implicating these as particularly likely 264 pathogenic factors underlying the GWAS loci. In the majority of these loci (N=22, 64.7%) the 265 266 eQTLs represented a single Ensembl gene, nominating it as the most well supported "risk gene", based on schizophrenia genetic risk coupled to expression features in the polyA+ 267 fraction of postmortem DLPFC (Figure 4 and Figure S9). Of the remaining 12 GWAS loci that 268 269 did not associate with features in only a single gene, 6 (17.6%) were similarly associated with 270 the expression of two nearby genes, which may indicate different candidate genes whose expression is driven by different chromosomal haplotypes (Table 2). The effects of the 271 272 remaining risk SNPs were more difficult to untangle, each associating with similar significance levels with three (N=2), four (N=3) or seven (N=1) genes. Finally, there were transcript-specific 273 274 signals for many of the loci, including individual isoforms among multi-gene risk eQTLs. For 275 example, there were 40 genes with transcript annotation (excluding gene- and region-level 276 summarizations) and 25 genes contained features tagging single Ensembl transcripts (Table 277 S17). This transcript specificity cautions that many gene count- or microarray-based approaches 278 may miss important risk gene signals in eQTL analyses (see Discussion). These eQTL results 279 highlight significant and independently-replicated risk-associated schizophrenia candidate 280 genes and their specific transcripts that comprise links in the causative chain of schizophrenia in 281 the human brain.

282

283 Discussion

We have explored the diverse landscape of expression correlates of schizophrenia risk and illness state in the postmortem human frontal cortex. Using deep RNA sequencing to define convergent measures of gene expression and early brain development, we identified widespread developmental regulation of transcription, including novel discoveries related to preferential isoform usage across brain development. These isoform "shifts" were associated with genetic risk for schizophrenia, and the directionality of dysregulation of developmentally

regulated features suggest a more fetal-like expression profile in patients with schizophrenia 290 291 compared to controls. Our approach to transcript characterization, which included extensive 292 characterization of unannotated sequence, revealed that many more schizophrenia risk 293 associated SNPs are brain eQTLs than previously reported - many risk SNPs only associate with a single gene, or even a single transcript, and many of these adult-identified eQTLs show 294 295 similar genetic regulation in the fetal brain. Lastly, we identified significant and replicated genes 296 differentially expressed in patients with schizophrenia compared to unaffected controls using a 297 new experiment-based statistical framework to estimate and reduce the effects of latent RNA 298 degradation bias. Without this new approach to RNA guality adjustment, replication across 299 datasets is markedly limited if not negligible, and the directionality of the association with developmental isoform shifts is anomalous. These data suggest a convergence of 300 developmental regulation and genetic risk for schizophrenia that appears relatively stable in 301 patients ascertained at death, following decades of illness after diagnosis. We previously 302 303 observed analogous stability of epigenetic marks highlighting prenatal life in adult patients with schizophrenia¹⁷, suggesting that both genetic and environmental risk factors implicated in 304 305 schizophrenia illness involve early developmental events which are still observable in the brain 306 tissue of adult individuals who have been ill for many years.

307 While our approach utilizing convergent expression features – genes, exons, transcripts, junctions, and expressed regions - results in more complicated data processing and analysis, it 308 309 can potentially cast a wider net in the search for valid biological signals in RNA sequencing 310 datasets. Using all convergent features overcomes the limitations related to any given feature 311 summarization, including the inability to measure and interrogate unannotated or novel transcribed sequence using gene and exon counts, and the difficulties in full transcript assembly 312 from short sequencing reads ¹⁹. We note that both quantifying and analyzing splice junctions. 313 and also transcript-level data, rely on junction-spanning reads for statistical power. In our data, 314 there were approximately 3 times (IQR: 2.86-3.24) more reads available by gene/exon counting 315 approaches than those that contain splice junctions, likely explaining why gene counts 316 317 discovered more differentially expressed genes in the schizophrenia diagnosis analyses. Two relatively new approaches utilized here - direct quantification and statistical analyses of splice 318 319 junction counts and expressed regions - can identify differential expression signal when it is 320 outside of the annotated transcriptome. The junction-level approach can also identify previously 321 uncharacterized novel transcribed sequence, which we replicated in other large publicly 322 available datasets, as well as delineate individual transcripts or classes of transcripts that share a particular splice junction, and as read lengths increase, the proportion of reads containing 323 splice junctions will increase, making junction- and transcript-based approaches even more 324 powerful, including those recently developed to identify splicing QTLs ²⁰. 325

Our analysis of RNA-seq data identified widespread shifts in preferential isoform use across brain development, which would have been impossible to identify using only gene-level data and incomplete with only exon-level data (Figure 4). The genes with these isoform shifts were significantly enriched for neurodevelopmental and cellular signaling processes, and as well as for genes in regions of genetic risk for schizophrenia. A prevalent hypothesis suggests that schizophrenia is a neurodevelopmental disorder that arises because of altered connectivity and plasticity in the early assembly of relevant neural circuits¹, and the potential convergence of

genetic risk with developing signaling processes across human brain development should point 333 334 to specific candidate molecular disruptions occurring during the wiring of the fetal brain. Indeed, inefficient or disrupted signaling and tuning is thought to underlie the expression of illness in the 335 adult brain¹, and the most successful therapeutics work through improving these processes¹⁴. 336 Consistent with this hypothesis, we find evidence for differences in the expression of genes 337 338 coding for subunits of ion channels in the cortices of patients with schizophrenia compared to 339 controls. We observed significant differential expression of both voltage-gated (KCNA1, KCNC3, 340 KCNK1, KCNN1, SCN9A) and ligand gated ion channels (GRIN3A, GABRA5, GABRB3), 341 transporters (SLC16A2, ALC25A33, SLC26A11, SLC35F2, SLC7A3), and ion channel auxiliary 342 subunits (KCNIP3, SCN1B), supporting other evidence that the clinical phenomenology of schizophrenia is associated with altered neuronal excitability²¹. While these findings implicating 343 basic mechanisms of cortical circuit dynamics may underlie fundamental aspects of the clinical 344 disorder, the possibility that they are driven by the effects of pharmacological treatment and are 345 thus state dependent epiphenomena cannot be excluded. 346

347 Our eQTL analyses are among the largest and most comprehensive to date in human brain tissue, requiring stringent genome-wide significance and independent replication, and offer 348 349 additional insights into the genetic regulation of RNA expression levels. We show that over half 350 of the genes with eQTL signals are associated with three or more nearby LD-independent 351 SNPs, suggesting a potential mechanism to explain how expression levels at the population-352 level are relatively normally distributed while so many genes show distinct eQTL signals. Our 353 data also suggest more widespread regulation of specific transcript isoforms, which we were 354 able to identify using exon- and junction-level analyses. This transcript-specific genetic regulation was particularly prevalent among schizophrenia risk variants, where 62.5% of loci 355 356 containing multiple transcripts showed clinically- and molecularly-consistent eQTL signal to a 357 single Ensembl transcript isoform. Overall, we have identified many more eQTLs to genomewide significant schizophrenia risk variants -42.5% - than previously reported, experimentally 358 359 implicating far more potential "risk" genes within these loci than previously characterized.

360 These eQTL associations within the genome-wide significant schizophrenia loci generate novel putative biological mechanisms underlying risk for the disorder. We highlight 34 361 GWAS loci that contain significant eQTLs that show convergence of consistent altered 362 expression across both genetic risk and case status in the human brain. These loci often point 363 364 to individual "risk" genes or even more specific "risk" transcripts that can represent targetable entry points for more focused cellular assays and model organism work to better characterize 365 schizophrenia risk mechanisms. Moreover, observation of convergence in directionality of 366 367 molecular association with genetic risk and clinical state identifies a compelling strategy and 368 directionality for target rescue, specifically to increase or decrease the function of the target transcript(s) and downstream effectors. Focusing solely on increased or decreased expression 369 370 in brains of patients compared to controls, without considering genetic risk variants and their regulation of local gene expression, will likely predominantly highlight molecular changes 371 resulting from the schizophrenia illness state, as we suggest with consistent down-regulation of 372 373 ion channels.

We stress the priority of identifying the most relevant cellular consequences of genetic risk, which we view as production of particular isoforms with predicted directionality, rather than trying to identify "causal" mutations tagged by "marker" risk SNPs from the GWAS. We suggest that identifying convergence between genetic risk and potential molecular consequences of the

- disorder is likely to result in better, or at least more consistent support for, targets for drug
- 379 discovery efforts.
- 380
- 381

382 Author Contributions

- A.E.J performed primary data processing and analyses, led the writing of the manuscript
- 384 R.E.S contributed to data analysis and writing of the manuscript
- J.H.S., R.T., Y.G. performed RNA sequencing data generation (RNA extraction, library
 preparation, and sequencing) and QC analyses
- L.C.T., J.T.L performed region-level data generation and assisted in data analysis and
 interpretation
- T.K.T.,S.X.,J.Q.,C.C.,B.J.M., A.C.,N.B.,BrainSeq provided feedback on manuscript and
 contributed to data analyses and interpretations on eQTL analyses.
- 391 B.U. created user-friendly database of eQTLs
- A.D.S., T.M.H., J.E.K.- collected, consented, characterized, and dissected human brain tissue
- 393 D.R.W. designed and oversaw the research project, wrote the manuscript
- 394 Tony Kam-Thong is employed by F. Hoffmann-La Roche
- 395 Hualin S Xi and Jie Quan are employees of Pfizer Inc.
- Alan Cross, and Nicholas J.Brandon were full time employees and shareholders in AstraZeneca
 at the time these studies were conducted.
- 398 The remaining authors declare no competing financial interests.
- 399
- Data Availability: sequencing reads and genotype data are available through SRA and dbGaP
 at accession numbers: [TBD] following publication.
- 402

403 Acknowledgements:

404 We thank Dr. Ronald Zielke, Robert D. Vigorito, and Robert M. Johnson of the National Institute 405 of Child Health and Human Development Brain and Tissue Bank for Developmental Disorders 406 at the University of Maryland for their provision of fetal, child, and adolescent brain specimens;

407 This work was supported by the funding from Lieber Institute for Brain Development and the

408 Maltz Research Laboratories. The work was partially supported by R21MH109956 to A.E.J.

L.C.T was supported by Consejo Nacional de Ciencia y Tecnología México 351535.

The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the 410 411 Office of the Director of the National Institutes of Health. Additional funds were provided by the NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Donors were enrolled at Biospecimen Source 412 Sites funded by NCI\SAIC-Frederick, Inc. (SAIC-F) subcontracts to the National Disease 413 Research Interchange (10XS170), Roswell Park Cancer Institute (10XS171), and Science Care, 414 Inc. (X10S172). The Laboratory, Data Analysis, and Coordinating Center (LDACC) was funded 415 through a contract (HHSN268201000029C) to The Broad Institute, Inc. Biorepository operations 416 were funded through an SAIC-F subcontract to Van Andel Institute (10ST1035). Additional data 417 418 repository and project management were provided by SAIC-F (HHSN261200800001E). The 419 Brain Bank was supported by a supplements to University of Miami grants DA006227 & DA033684 and to contract N01MH000028. Statistical Methods development grants were made 420 to the University of Geneva (MH090941 & MH101814), the University of Chicago (MH090951, 421 422 MH090937, MH101820, MH101825), the University of North Carolina - Chapel Hill (MH090936 & MH101819), Harvard University (MH090948), Stanford University (MH101782), Washington 423 University St Louis (MH101810), and the University of Pennsylvania (MH101822). The data 424 425 used for the analyses described in this manuscript were obtained from dbGaP accession

426 number <u>phs000424.v6.p1</u> on October 6, 2015.

427 Data were generated as part of the CommonMind Consortium supported by funding from 428 Takeda Pharmaceuticals Company Limited, F. Hoffman-La Roche Ltd and NIH grants R01MH085542, R01MH093725, P50MH066392, P50MH080405, R01MH097276, RO1-MH-429 430 075916, P50M096891, P50MH084053S1, R37MH057881 and R37MH057881S1, HHSN271201300031C, AG02219, AG05138 and MH06692. Brain tissue for the study was 431 obtained from the following brain bank collections: the Mount Sinai NIH Brain and Tissue 432 433 Repository, the University of Pennsylvania Alzheimer's Disease Core Center, the University of Pittsburgh NeuroBioBank and Brain and Tissue Repositories and the NIMH Human Brain 434 Collection Core. CMC Leadership: Pamela Sklar, Joseph Buxbaum (Icahn School of Medicine 435 at Mount Sinai), Bernie Devlin, David Lewis (University of Pittsburgh), Raguel Gur, Chang-Gyu 436 437 Hahn (University of Pennsylvania), Keisuke Hirai, Hiroyoshi Toyoshiba (Takeda Pharmaceuticals Company Limited), Enrico Domenici, Laurent Essioux (F. Hoffman-La Roche 438 Ltd), Lara Mangravite, Mette Peters (Sage Bionetworks), Thomas Lehner, Barbara Lipska 439 440 (NIMH).

Members of the BrainSeq consortium include: Christian R. Schubert, Patricio O'Donnell, Jie
Quan, Jens R. Wendland, Hualin S. Xi, Ashley R. Winslow, Enrico Domenici, Laurent Essioux,
Tony Kam-Thong, David C. Airey, John N. Calley, David A. Collier, Hong Wang, Brian
Eastwood, Philip Ebert, Yushi Liu, Laura Nisenbaum, Cara Ruble, James E. Scherschel, Ryan
Matthew Smith, Hui-Rong Qian, Kalpana Merchant, Michael Didriksen, Mitsuyuki Matsumoto,
Takeshi Saito, Nicholas J. Brandon, Alan J. Cross, Qi Wang, Husseini Manji, Hartmuth Kolb,

447 Maura Furey, Wayne C. Drevets, Joo Heon Shin, Andrew E. Jaffe, Yankai Jia, Richard E.

448 Straub, Amy Deep-Soboslay, Thomas M. Hyde, Joel E. Kleinman, Daniel R. Weinberger

449

450 Figure Legends

Figure 1: Developmental regulation of expression. (A) Principal component #1 of the gene-level 451 expression data versus age; PCW: post-conception weeks, remaining ages are in years. (B) 452 Expression features fall into two main development regulation signatures, increasing in 453 454 expression from fetal to postnatal life (orange) or decreasing from fetal to postnatal life (blue). Y-455 axis is Z-scaled expression (to standard normal), dark lines represent median expression levels, and confidence bands represent 25th-75th percentiles of expression levels for each class of 456 features. (C) KEGG pathways enriched for genes with isoform shifts, stratified by which feature 457 type identified the gene as having a switch. Coloring/scaling represents -log10(FDR) for gene 458 459 set enrichment. Analogous data for GO gene sets (biological processes, BP, and molecular function, MF) are available in Table S6. DER: differentially expressed region. Enrichment 460 461 analyses for isoform shift genes among PGC2 schizophrenia GWAS risk loci with exon and 462 junction counts using both (D) parametric p-values) and (E) permutation-based p-values. OR: 463 odds ratio.

Figure 2: Differential expression comparing patients with schizophrenia to controls. (A) 464 Histogram of fold changes of the diagnosis effect of those features that were significant and 465 466 independently replicated, colored by feature type. (B) Gene set analyses of genes with decreased expression in patients compared to controls by feature type. Coloring/scaling 467 468 represents -log10(FDR) for gene set enrichment. Significant directional effects of developmental 469 regulation among diagnosis-associated features for those features that (C) increased and (D) 470 decreased across development (i.e. those features shown in Figure 1B). P-values provided for Wilcoxon rank sign test for those features developmentally regulated among case-control 471 differences to those not developmentally regulated. 472

473 Figure 3: Expression quantitative trait loci (eQTL) in the human brain. (A) Table summarizing 474 eQTL results across the five feature summarization types (gene, exon, transcript, junction and expressed region). Bonf: Bonferroni-adjusted p-value, Ens: Ensembl, Sym: Symbol, IQR: 475 interquartile range, 25th-75th percentiles, bp = base pairs, kb = kilobases. (B) Similar 476 standardized effect sizes (T-statistics) for eQTLs identified in full sample within just Caucasian 477 478 (CAUC) and African American (AA) computed separately, here using exon-level eQTL results. 479 (C) Histogram of the distance of the most significant SNP to each eQTL expression feature. (D) 480 Boxplots of the effect sizes (absolute fold changes per minor allele copy) stratified by feature 481 type.

Figure 4: Clinical enrichment of schizophrenia risk. (A) Image describing enforcement of
directional consistency between GWAS, eQTL, and case-control differences. We highlight
example eQTLs to GWAS-positive variants among annotated exons in (B) *SRR* and (C) *STAT6*,
as well as unannotated expressed features, for example an intronic region in (D) *HSPD1 /HSPE1*, shown as a star in (E), and a junction linked to (F) only one annotated exon of

- 487 IMMP2L, shown as a bar in (G). In panels E and G, dark blue: exon, light blue: intron;
- 488 coordinates relative to hg19.

489 Tables

		Transcript Class			
Number	Datasets	In Ensembl	Exon Skip	Alt Boundary	Novel
	Neither	2680(1.3%)	118(1.4%)	315(1.6%)	4613(24.8%)
251557	Geuvadis	134(0.1%)	3(0%)	14(0.1%)	116(0.6%)
	GTEX	7883(3.8%)	1257(14.8%)	4312(22.3%)	6768(36.3%)
	Both	194342(94.8%)	7136(83.8%)	14730(76%)	7136(38.3%)

490

- 491 **Table 1:** splice junction annotation and characterization in GTEx and GEUVADIS for moderately
- 492 expressed junctions (mean reads per 80M mapped reads, RP80M > 1). Each column
- 493 represents a 2x2 table for presence of identified junctions in 495 DLPFC samples in two

494 independent polyA+ datasets.

495

496

GWAS	Risk	Gene	Feature	Best p-
Rank	Direction		Туре	value
3	UP	AS3MT	E	6.73E-40
3	UP	BORCS7 ⁺	G,E,R	9.23E-34
3	UP	AS3MT*	J	9.57E-25
7	DOWN	FTSJ2	E,J,G,R	2.64E-07
8	DOWN	GNL3LP1	E	3.11E-10
8	DOWN	ERCC8	E,R	6.22E-10
9	DOWN	ARL6IP4	J	4.12E-36
16	UP	IMMP2L	J,T	6.04E-10
17	UP	SNX19	J	9.77E-07
23	UP	C2orf82	Т	6.33E-06
24	DOWN	NRGN	R	3.5E-05
24	DOWN	VSIG2	R	8.6E-05
31	UP	GOLGA2P7	E,R	5.12E-30
31 UP		GOLGA6L5P	R	8.13E-24
33	UP	HSPD1	R	3.34E-14
34	UP	XPNPEP3	E,J,R	3.63E-08
42	DOWN	PCCB	G,E,R	2.95E-11
47	DOWN	SRR	E,G,R,J	2.1E-12
51	DOWN	GATAD2A	R	2.51E-08
51	DOWN	NDUFA13	J	9.36E-06
52	UP	VPS45	R	1.88E-16
57	57 UP RERE		E	7.7E-07
73	UP	CTNNA1	E	5.18E-07
84	84 UP GF		R	3.12E-06
94	94 UP <i>PF</i>		R,J,E	5.37E-09
94	UP TSNAXIP		G,R	8.78E-06
96	DOWN ATPAF2		E	4.58E-07
103	UP	STAT6	E,J	1.71E-07
106	DOWN	SOX2-OT	R	8.18E-12
106	DOWN	RP11-275H4.1	Т	2.62E-06
117	DOWN	FANCL	E,R	2.45E-17
120	DOWN	BRINP2	R	6.7E-06
121	UP	CD46	E,R,G,J	1.57E-37
125	UP	IRF3	J,E	4.51E-10

Table 2: eQTL and clinical directional consistent signal around the GWAS risk variants for 497 schizophrenia. GWAS rank is relative to Supplementary Table 2 in Ripke et al ². Direction refers 498 to whether schizophrenia risk represents increased or decreased expression of the particular 499 500 features. Feature type indicates which of (G)enes, (E)xons, (J)unctions, (T)ranscripts, or expressed (R)egions showed eQTL association to the risk SNP. The best p-value for the risk 501 SNP to features in each gene are recorded in the last column. +C10orf32 in Ensembl v75 but 502 updated in later versions; * unannotated junction found to tag a new transcript of the gene, 503 AS3MT^{d2d3}, that has been more fully characterized by Li et al²². 504

505

506

507 References

508	1	Weinberger, D. R. & Levitt, P. in Schizophrenia 393-412 (Wiley-Blackwell, 2011).
508	2	Ripke, S. <i>et al.</i> Biological insights from 108 schizophrenia-associated genetic loci.
510	-	<i>Nature</i> 511 , 421-+, doi:10.1038/nature13595 (2014).
511	3	Maurano, M. T. et al. Systematic localization of common disease-associated variation in
512		regulatory DNA. Science 337, 1190-1195, doi:10.1126/science.1222794 (2012).
513	4	Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from
514	-	RNA-seq reads. <i>Nature biotechnology</i> 33 , 290-295, doi:10.1038/nbt.3122 (2015).
515 516	5	Nellore, A. <i>et al.</i> Human splicing diversity across the Sequence Read Archive. <i>bioRxiv</i> , doi:10.1101/038224 (2016).
516 517	6	Collado Torres, L. <i>et al.</i> Flexible expressed region analysis for RNA-seq with derfinder.
518	U	Nucleic Acids Research In Press., doi:10.1101/015370 (2016).
519	7	Jaffe, A. E. <i>et al.</i> Developmental regulation of human cortex transcription and its clinical
520		relevance at single base resolution. Nat Neurosci 18, 154-161, doi:10.1038/nn.3898
521		(2015).
522	8	Tan, W. et al. Molecular cloning of a brain-specific, developmentally regulated
523		neuregulin 1 (NRG1) isoform and identification of a functional promoter variant
524		associated with schizophrenia. <i>The Journal of biological chemistry</i> 282 , 24343-24351,
525 526	9	doi:10.1074/jbc.M702953200 (2007). Kao, W. T. <i>et al.</i> Common genetic variation in Neuregulin 3 (NRG3) influences risk for
520	9	schizophrenia and impacts NRG3 expression in human brain. <i>Proceedings of the</i>
528		National Academy of Sciences of the United States of America 107 , 15619-15624,
529		doi:10.1073/pnas.1005410107 (2010).
530	10	Tao, R. et al. Expression of ZNF804A in human brain and alterations in schizophrenia,
531		bipolar disorder, and major depressive disorder: a novel transcript fetally regulated by
532		the psychosis risk variant rs1344706. <i>JAMA psychiatry</i> 71 , 1112-1120,
533		doi:10.1001/jamapsychiatry.2014.1079 (2014).
534	11	Hyde, T. M. <i>et al.</i> Expression of GABA signaling molecules KCC2, NKCC1, and GAD1 in cortical development and schizophrenia. <i>The Journal of neuroscience : the official</i>
535 536		journal of the Society for Neuroscience 31 , 11088-11095,
537		doi:10.1523/JNEUROSCI.1234-11.2011 (2011).
538	12	Birnbaum, R., Jaffe, A. E., Hyde, T. M., Kleinman, J. E. & Weinberger, D. R. Prenatal
539		expression patterns of genes associated with neuropsychiatric disorders. The American
540		<i>journal of psychiatry</i> 171 , 758-767, doi:10.1176/appi.ajp.2014.13111452 (2014).
541	13	Buchanan, R. W. & Carpenter, W. T. Domains of psychopathology: an approach to the
542		reduction of heterogeneity in schizophrenia. <i>The Journal of nervous and mental disease</i>
543	11	182 , 193-204 (1994).
544 545	14	Winterer, G. & Weinberger, D. R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. <i>Trends in neurosciences</i> 27 , 683-690, doi:10.1016/j.tins.2004.08.002
546		(2004).
547	15	Jaffe, A. E. <i>et al.</i> A framework for RNA quality correction in differential expression
548	-	analysis. <i>bioRxiv</i> , doi:10.1101/074245 (2016).
549	16	Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from
550		108 schizophrenia-associated genetic loci. Nature 511, 421-427,
551	. –	doi:10.1038/nature13595 (2014).
552	17	Jaffe, A. E. <i>et al.</i> Mapping DNA methylation across development, genotype and
553 554		schizophrenia in the human frontal cortex. <i>Nature neuroscience</i> 19 , 40-47, doi:10.1038/nn.4181 (2016).
554		

555 556 557 558 559 560 561 562 563 564 565	18 19 20 21 22	 Hannon, E. <i>et al.</i> Methylation QTLs in the developing brain and their enrichment in schizophrenia risk loci. <i>Nature neuroscience</i> 19, 48-54, doi:10.1038/nn.4182 (2016). Steijger, T. <i>et al.</i> Assessment of transcript reconstruction methods for RNA-seq. <i>Nature methods</i> 10, 1177-1184, doi:10.1038/nmeth.2714 (2013). Li, Y. I. <i>et al.</i> RNA splicing is a primary link between genetic variation and disease. <i>Science</i> 352, 600-604, doi:10.1126/science.aad9417 (2016). Uhlhaas, P. J. & Singer, W. Abnormal neural oscillations and synchrony in schizophrenia. <i>Nature reviews. Neuroscience</i> 11, 100-113, doi:10.1038/nrn2774 (2010). Li, M. <i>et al.</i> A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus. <i>Nature medicine</i>, doi:10.1038/nm.4096 (2016).
566		
567		
568	Metho	ods
569		
570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 583 584 585 586 587 588	Post-r Medic Distric NIMH/ brain t Develo under Univer tissue Transf neurop and su tissue neurop previo fashio	nortem brain samples nortem human brain tissue was obtained by autopsy primarily from the Offices of the Chief al Examiner of the District of Columbia, and of the Commonwealth of Virginia, Northern t, all with informed consent from the legal next of kin (protocol 90-M-0142 approved by the 'NIH Institutional Review Board). Additional post-mortem fetal, infant, child and adolescent issue samples were provided by the National Institute of Child Health and Human opment Brain and Tissue Bank for Developmental Disorders (http://www.BTBank.org) contracts NO1-HD-4-3368 and NO1-HD-4-3383. The Institutional Review Board of the rsity of Maryland at Baltimore and the State of Maryland approved the protocol, and the was donated to the Lieber Institute for Brain Development under the terms of a Material fer Agreement. Clinical characterization, diagnoses, and macro- and microscopic pathological examinations were performed on all samples using a standardized paradigm, ubjects with evidence of macro- or microscopic neuropathology were excluded. Details of acquisition, handling, processing, dissection, clinical characterization, diagnoses, pathological examinations, RNA extraction and quality control measures were described usly in Lipska, et al. ²³ . The Brain and Tissue Bank cases were handled in a similar n (http://medschool.umaryland.edu/BTBank/ProtocolMethods.html). Antipsychotic use neasured using toxicology at time of death.

589 RNA extraction and sequencing

590 Post-mortem tissue homogenates of dorsolateral prefrontal cortex grey matter (DLPFC)

approximating BA46/9 in postnatal samples and the corresponding region of PFC in fetal

samples were obtained from all subjects. Total RNA was extracted from ~100 mg of tissue using

the RNeasy kit (Qiagen) according to the manufacturer's protocol. The poly-A containing RNA

594 molecules were purified from 1 µg DNAse treated total RNA and sequencing libraries were

constructed using the Illumina TruSeq© RNA Sample Preparation v2 kit. Sequencing

596 indices/barcodes were inserted into Illumina adapters allowing samples to be multiplexed in

across lanes in each flow cell. These products were then purified and enriched with PCR to

598 create the final cDNA library for high throughput sequencing using an Illumina HiSeq 2000 with

599 paired end 2x100bp reads.

600

601 RNA sequencing data processing

602

The Illumina Real Time Analysis (RTA) module performed image analysis, base calling, and the BCL Converter (CASAVA v1.8.2), generating FASTQ files containing the sequencing reads. These reads were aligned to the human genome (UCSC hg19 build) using the spliced-read mapper TopHat (v2.0.4) using the reference transcriptome to initially guide alignment, based on known transcripts of the previous Ensembl build GRCh37.67 (the "–G" argument in the software) ²⁴. We achieved a median of 85.3 million (IQR: 71.7M-111.2M) aligned reads per sample (see Table S1).

610

611 We characterized the transcriptomes of these 495 samples using five convergent

612 measurements of expression ("feature summarizations")– (1) gene and (2) exon counts, and (3) 613 transcript-level quantifications that rely on existing gene annotation, and two annotation-

agnostic approaches we have developed that are determined solely from the read alignments –

615 (4) read coverage supporting exon-exon splice junctions (e.g. coordinates of potentially intronic

sequence that are spliced out of mature transcripts captured by a single read) and (5) read

617 coverage overlapping each base in each sample which we have summarized into contiguous

618 "expressed regions" (ERs, see Methods, Figure S1). These last three measurements generate

619 expression for features of interest that can "tag" elements of transcripts in the data that are not 620 constrained by limitations or incompleteness of existing annotation, and the counts for these

621 features can then be directly used for differential expression analysis.

1. Gene counts were generated using the featureCounts tool²⁵ based on the more recent

- Ensembl v75, which was the last stable release for the hg19 genome build, using single end read counting [featureCounts –a \$GTF –o \$OUT \$BAM]. We converted counts to RPKM values using the total number of aligned reads across the autosomal and sex chromosomes (dropping reads mapping to the mitochondria chromosome).
- Exon counts were also generated using the featureCounts tool²⁵ based on the more recent
 Ensembl v75, using single end read counting, and allowing reads to be assigned to multiple
 exons (e.g. those with splice junctions) [featureCounts –O –f –a \$GTF –o \$OUT \$BAM]. We
 converted counts to RPKM values using the total number of aligned reads across the
 autosomal and sex chromosomes (dropping reads mapping to the mitochondria
- 632 chromosome).

3. Junction counts were generated by first filtering the TopHat BAM file to primary alignments
only [samtools view -bh -F 0x100 \$BAM > \$NEWBAM] and regtools ²⁶ was used to extract
analogous junction information (coordinates and number of reads supporting) as the TopHat
output. We found that native TopHat output (junctions.bed) was based on both primary and
secondary alignments, which could influence the degree of potentially novel splice junctions.
We used a modified version of TopHat's "bed_to_juncs" program to retain the number of
supporting reads (in addition to returning the coordinates of the spliced sequence, rather

than the maximum fragment range), and used R code (see Supplementary Code) to 640 641 combine and annotate these junctions across all samples. We annotated identified splice junctions using Ensembl v75 – while the initial alignment was guided by Ensembl v67, novel 642 junctions, by definition, are identified in the second genome alignment, rather than the initial 643 guided transcriptome alignment step. We converted counts to "RP80M" values, or "reads per 644 80 million mapped" using the total number of aligned reads across the autosomal and sex 645 chromosomes (dropping reads mapping to the mitochondria chromosome), which can be 646 647 interpreted as the number of reads supporting the junction in an average library size (we were targeting 80M reads in the sequencing). Most junctions were lowly expressed in our 648 649 homogenate tissue, with fewer than 1 average normalized supporting read (N=3,330,642; 650 92.98%) including approximately half unique to a single individual (N = 1.779.241, 49.67%).

- 4. Transcripts were assembled using StringTie⁴ (version 1.1.2) guided by Ensembl v75 651 annotation within each sample [stringtie \$BAM -o \$OUT -G \$GTF]. We then used 652 "CuffMerge"²⁷ to merge all assembled transcriptomes across all samples, and then re-653 654 quantified the expression of each transcript isoform in each sample again using StringTie to 655 this global set of transcripts [stringtie \$BAM -B -e -o \$OUT -G \$GTF_ALL] to have expression measurements on the same transcripts across all samples. We then used the 656 "ballgown" tool²⁸ to merge all assembled and guantified transcripts across all samples (N= 657 733,339), and used liberal filtering to remove lowly or uniquely expressed transcripts (mean 658 FPKM > 0.025), resulting in 188,578 transcripts across the 495 samples. 659
- 5. Expressed regions (ERs) were calculated using the "derfinder" R Bioconductor package⁶
 using a cutoff of 5 normalized (to 80M reads) read coverage, which identified 389,797 ERs.
 We retained the 275,885 ERs that were at least 12 basepairs, and annotated the ERs to
 Ensembl v75.
- 664

665 <u>Genotype data processing</u>

SNP genotyping with HumanHap650Y V3 (N=135), Human 1M-Duo V3 (N=357), and Omni5 666 (N=3) BeadChips (Illumina, San Diego, CA) was carried out according to the manufacturer's 667 instructions with DNA extracted from cerebellar tissue. Genotype data were processed and 668 normalized with the crimm R/Bioconductor package²⁹ separately by platform. Genotype 669 imputation was performed on high-quality observed genotypes (removing low quality and rare 670 671 variants) using the prephasing/imputation stepwise approach implemented in IMPUTE2³⁰ and Shape-IT³¹, with the imputation reference set from the full 1000 Human Genomes Project Phase 672 3 data set, separately by platform. We retained common SNPs (MAF > 5%) that were present in 673 the majority of samples (missingness < 10%) that were in Hardy Weinberg equilibrium (at p > 674 1x10⁻⁶) using the Plink³² version 1.9 tool kit [`plink --bfile \$BFILE --geno 0.1 --maf 0.05 --hwe 675 0.000001`]. We then identified linkage disequilibrium (LD)-independent SNPs to use in genome-676 677 wide clustering of samples and in the number of independent eQTL tests performed [`plink bfile \$BFILE --indep 100 10 1.25]. Multidimensional scaling (MDS) was performed on the 678 679 autosomal LD-independent construct genomic ancestry components on each sample, which can 680 be interpreted as quantitative levels of ethnicity - the first component separated the Caucasian 681 and African American samples. This processing and quality control steps resulted in 7,421,423 common variants in this dataset of 495 subjects. 682

683

684 <u>Risk polygene score (RPS) analysis</u>

We computed risk polygene scores (RPS) using the allelic dosage files following imputation 685 described above and the SNPs from provided by the PGC to the Lieber Institute that did not 686 contain completely different clinical subjects used in the GWAS². We considered expression 687 associations at the gene, exon and junction-level to the RPS scores from the first 5 clinical SNP 688 sets. corresponding to GWAS p-value thresholds of p < 5e-8 (s1), p < 1e-6 (s2), p < 1e-4 (s3), p 689 < 0.001 (s4), and p < 0.01 (s5) – subsequent SNP sets were ignored due to clinical risk 690 plateauing at s5. We also focused only on Caucasian individuals (96 cases, 113 controls), as 691 the s5 RPS was increased in patients relative to controls in this sample (p=3.2x10⁻⁵), but did not 692 differ among African Americans (p=0.9). Within each expression feature type, we modeled 693 expression levels as a function of each RPS set (s1-s5), adjusting for 3 MDS components of the 694 genotype data, sex, and the first K principal components (PCs) of the normalized expression 695 696 features, where K was calculated using the Buja and Eyuboglu permutation-based algorithm³³ in the "sva" Bioconductor package³⁴. The resulting p-values of RPS on expression, adjusting for 697 the above factors, were subject to false discovery rate (FDR) control to account for multiple 698 699 testina.

700

701 Public data processing

GTEx: Raw RNA-seq reads from all brain samples with corresponding genotype data were 702 downloaded from SRA and aligned to the genome using TopHat2²⁴ (version 2.0.14) using the 703 iGenomes transcriptome and genome annotations based on hg19. As above, featureCounts²⁵ 704 was used to quantify expression of genes and exons relative to Ensembl v75, and junctions 705 were quantified with regtools²⁶ as above. We used StringTie with the assembled merged GTF 706 from the LIBD DLPFC samples on the GTEx BAM files to quantify the same transcripts, and 707 used bwtool to quantify the coverage of the same expressed regions from the GTEx brain 708 samples. Genotype data from the two platforms (Illumina Omni 5M and 2.5M) were imputed 709 separately as described above and merged into a single plink³² set. 710

- 711 GEUVADIS: Raw RNA-seq reads from all LCL samples were downloaded from SRA and
- aligned to the genome using TopHat2 ²⁴ (version 2.0.9) using the iGenomes transcriptome and
- genome annotations based on hg19. As above, featureCounts²⁵ was used to quantify
- expression of genes and exons relative to Ensembl v75, and junctions were quantified with
- regtools²⁶ as above. We used StringTie with the assembled merged GTF from the LIBD DLPFC
- samples on the GEUVADIS BAM files to quantify the same transcripts, and used bwtool to
- quantify the coverage of the same expressed regions from the GEUVADIS LCL samples.
- 718 *CommonMind Consortium (CMC)*: 547 BAM files were downloaded from Synapse, which were
- aligned with TopHat2 (version 2.0.9) using Ensembl v70 transcriptome annotation and the hg19
- genome. As above, featureCounts ²⁵ was used to quantify expression of genes and exons
- relative to Ensembl v75, and junctions were quantified with regtools ²⁶ as above. We used
- 522 StringTie with the assembled merged GTF from the LIBD DLPFC samples on the CMC BAM
- files to quantify the same transcripts, and used bwtool to quantify the coverage of the same

expressed regions from the CMC brain samples. Genotypes were converted to plink file sets

- from GEN files obtained from Synapse using posterior probabilities > 90%, resulting in genotype
- data across 9,506,038 SNPs and 547 samples.
- 727

728 Differential expression across brain development

We modeled differential expression across age at each of the five feature summarizations 729 (gene, exon, junction, transcript, and ER) in the 320 control subjects across the lifespan. We 730 731 modeled expression, after transforming with log2 with an offset of 1, as a function of age after 732 creating using linear splines with breakpoints at ages: birth (0), 1, 10, 20, and 50, further adjusting for sex and ancestry/ethnicity (first 3 MDS components). F-statistics were computed 733 comparing the model containing age (including the linear splines), sex, and ethnicity, to a 734 statistical model with just sex and ethnicity, with corresponding p-values calculated based on an 735 736 F-distribution with 11 and 308 degrees of freedom, and Bonferroni adjustment within each feature type was performed using the number of features with non-zero expression (gene 737 738 RPKM > 0.01, exon RPKM > 0.1, and junction RP80M > 0.2 with non-novel annotation) across 739 all samples as the number of tests (which varied by feature type). We also computed post-hoc 740 statistics on the data, including the Pearson correlation between "cleaned" expression (after 741 regressing out the effects of sex and ethnicity, holding the age effects constant), and age to 742 determine if the expression of the fetal rose or fell across the lifespan, and also measured the 743 fetal versus postnatal log₂ fold changes.

Preferential isoform usage across aging was determined by identifying the subset of genes (by 744 745 Ensembl ID) that contained at least one Bonferroni-significant feature that had positive 746 correlation with age and another Bonferroni-significant feature that had negative correlation with age. We also computed the difference in positive and negative correlations as a measure of the 747 magnitude of the preferential isoform use. Gene set analyses using pre-defined gene ontology 748 (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) sets were performed using the 749 clusterProfiler R/Bioconductor package³⁵, here using the genes (mapping from Ensembl to 750 751 Entrez ID) that had such preferential isoform use to those that were developmentally regulated (having at least one feature that was associate with age at Bonferroni significance). 752 753 Enrichments with the PGC2 schizophrenia risk loci – defined by the chr:start-end roughly 754 corresponding to linkage disequilibrium blocks in the published manuscript - were performed both parametrically, by overlapping the genomic coordinates of the 108 risk regions with those 755 756 genes that had preferential isoform usage, compared to a background of all genes with each set 757 of expressed features, as well as by permuting the locations of the 108 regions across the 758 genome 10,000 times and each time, re-computing the overlap within these null regions - see additional details in Jaffe et al 2015⁷. Empirical p-values were calculated by counting the 759 760 number of the odds ratios across the 10,000 null permutations to each observed odds ratio.

761

762 Schizophrenia differential expression analyses

763 Discovery dataset analysis: we first filtered the subjects with RNA-seq to retain a more stringent

- set of 155 SCZD cases and 196 controls (criteria: ages between 17-80, gene assignment rate >
- 0.5, mapping rate > 0.7, RIN > 6, not outlying on 2nd ancestry PC, only self-reported
- 766 Caucasians and African Americans). We fit three statistical models across each of the
- respression summarizations, modeling \log_2 transformed expression (with an offset of 1) as a
- 768 function of:
- (1) Adjusted ("_adj" suffix in supplementary tables): SCZD diagnosis, adjusting for age, sex,
- ancestry (SNP PCs 1, 5, 6, 9, 10, which were at least marginally associated with diagnosis), and
 then observed measures related to RNA quality: RIN, mitochondrial mapping rate, and gene
- assignment rate.
- (2) Adjusted + Quality Surrogate Variables ("_qsva" suffix in supplementary tables): SCZD
- diagnosis adjusting for "Adjusted" model as well as the first 12 PCs from the degradation matrix
- (see below) based on polyA+ libraries (selected using to using the BE algorithm ³³ in the sva
- Bioconductor package³⁴ while providing the adjusted model as input).
- (3) Adjusted + Principal Components ("_pca" suffix in supplementary tables): SCZD diagnosis
- adjusting for "Adjusted" model as well as the first *k* PCs from the expressed features (using the
- 50000 most variable features) depending on the feature type (gene: 23 PCs, exon: 20 PCs,
- 780 transcript: 26 PCs, junction: 26 PCs, ERs: 23 PCs).
- 781 We used the `ImTest` and `ebayes` functions in the limma Bioconductor package ³⁶ to fit all of
- the statistical models to estimate log₂ fold changes, moderated T-statistics, and corresponding
- p-values. Multiple testing correction via the false discovery rate (FDR) was applied using the set
- of expressed features in this sample set for each summarization type: 24,122 genes (mean
- 785 RPKM > 0.1), 420,022 exons (mean RPKM > 0.2), 61,950 transcripts (mean FPKM > 0.2),
- 786 229,846 junctions (mean RP80M > 1), and the 275,885 ERs.
- 787

RNA quality correction: We summarize the RNA quality correction approach here – for more
 detail, see the companion paper by Jaffe et al 2016 ¹⁵. Briefly, the quality surrogate variable
 analysis (qSVA) uses RNA sequencing data generated from five DLPFC tissue samples left
 unfrozen for 0, 15, 30 and 60 minutes, resulting in 20 RNA samples. These samples were
 sequenced with both polyA+ and RiboZero library preparations, and gene, exon and junction
 counts were derived as above. We utilized the gene-level effects of degradation in these data in
 Figure S5 to demonstrate residual confounding by RNA quality, which we call the "DEQual Plot".

For a given preparation type, we identified the genomic regions most susceptible to degradation by correlating coverage at expressed regions ⁶ to degradation time, adjusting for donor. This statistical modeling identified 515 regions significantly susceptible to degradation (at Bonferroni significance) in the RiboZero libraries and the top 1000 regions most susceptible to degradation (among the 35,287 at Bonferroni significance) in the polyA+ libraries – the BED files for these degradation-susceptible regions are available at: https://github.com/nellore/region_matrix.

- 801 The algorithm then involves selecting the set of regions for a particular library type and
- calculating total coverage within each region in the new user-provided samples (e.g. the 495
- 803 DLPFC RNA-seq polyA+ samples) to form the degradation matrix (which is either 515 or 1000
- rows by N samples). Then PCA is performed on the log2 transformed degradation matrix (with
- an offset of 1) and the top K PCs are selected, for example using the BE algorithm ³³, and
- 806 extracted the set of these PCs are referred to as quality surrogate variables (qSVs), and are
- 807 included as adjustment variables in subsequent differential expression analyses.
- *Replication dataset analysis:* we performed analogous sample selection procedures as in the
 discovery dataset to select 159 patients and 172 controls (total gene assignment rate > 0.3,
 alignment rate > 0.8, RIN > 6, ages between 18-80, non-outlying on genetic ancestry PCs 3 and
 5 and keeping only reported Caucasians and African Americans). We similarly fit the three sets
 of statistical models to all five feature summarizations, with the following differences compared
- 813 to the discovery analysis:
- (1) Adjusted model: the model here was diagnosis adjusting for age, sex, race, brain bank, RIN,gene assignment rate, alignment rate.
- 816 (2) qSVA model: the degradation matrix was constructed using the 515 regions based on the817 RiboZero libraries in the degradation experiment.
- (3) PC adjustment: for each feature summarization type, we included: 27 PCs for genes, 29 PCs
 for exons, 39 PCs for transcripts, 39 PCs for junctions, and 33 PCs for ERs.
- 820 In these replication data we did not perform FDR correction. We were using the study for
- replication, not discovery, and therefore only used the features that were expressed in our data
- regardless of the expression levels in CMC. We considered features independently replicated if
- they had the same directionality for the SCZD versus control \log_2 fold change and were
- marginally significant (at p < 0.05) in the CMC dataset.
- Gene set analyses on replicated differentially expressed features and genes were performed with clusterProfiler³⁵ as described above. Set-level analyses on features in the GWAS risk regions were conducted by assigning each expressed feature a binary variable for whether it was in the risk regions or not. Then we fit a linear regression model of the t-statistics for diagnosis, adjusted by the qSVA approach, as a function as whether the feature was in the risk region, adjusting for its average expression level. This analysis was conducted across and then within each of the five feature summarization types.
- 832

833 eQTL discovery analyses

- 834 We performed eQTL analyses separately by feature type (gene, exon, junction, transcript, and
- ER) allowing for a 500kb window around each of the 7,421,423 common SNPs in the 412 age >
- 13 samples, adjusting for ancestry (first three MDS components from the genotype data), sex,
- diagnosis, and the first *K* principal components (PCs) of the normalized expression features,
- 838 where *K* was calculated separately by feature type using the Buja and Eyuboglu permutation-

based algorithm³³ in the "sva" Bioconductor package³⁴ (gene: 22 PCs, exon: 19 PCs, junction: 839 840 26 PCs, transcript: 25 PCs, expressed regions: 20 PCs). The eQTL analyses were run using the MatrixEQTL R package³⁷, which returned the log₂ fold change per allele copy, and 841 corresponding T-statistic, p-value, and FDR for each SNP-feature pair. We further used the LD-842 independent SNPs to estimate the effective number of tests (by counting the number of features 843 844 within a 500kb window around each LD independent SNP) for a more conservative Bonferroni adjustment. For all five feature types, we retained all eQTLs with FDR < 1%. We retained the 845 846 best SNP for each expression feature for more detailed annotation and we calculated post-hoc 847 statistics separately by reported race (Caucasian or African American) using corresponding 848 subsets of the same design matrix.

849 <u>eQTL replication analyses</u>

850 We sought to replicate the best SNP-Feature pair for each eQTL in two independent datasets:

851 CommonMind Consortium and the GTEx project. As not every single SNP imputed in the

discovery dataset was present in each of CMC and GTEx, we retained the most highly ranked

(by eQTL p-value) SNP that was present in each dataset, and tested these SNP-Feature pairs

854 for replication.

855 *CommonMind Consortium*: for the ranked eQTL lists for each feature type (gene, exon, junction, 856 transcript, and ER), we retained the best discovery SNP present in the replication dataset. The 857 majority of these tested SNP-Feature pairs used the SNP with the best discovery p-value. For 858 example, among 1,812,008 FDR-significant SNP-Gene pairs, 1,539,218 pairs were present in CMC (84.9%), and among the 18,394 genes with at least one FDR-significant SNP, 14,928 859 (81.1%) of the top ranked SNPs were present, and therefore used for replication. Another 2.279 860 genes had FDR-significant SNPs more lowly ranked in the discovery set that were tested for 861 replication, and 1,187 genes did not have any FDR-significant SNPs present in CMC. The 862 863 proportions of present top-ranked SNPs retained for replication were similar across the different 864 feature summarizations: gene=81.1%, exon=82.1%, junction=81.5%, ER=80.6%, transcript=79.4%. The number of tested SNP-feature pairs across all expression 865 summarizations is provided in Table S9. 866

We calculated the corresponding principal components (PCs) across all expression features 867 868 separately in the 547 samples, as in the discovery data, and in our tests for replication, modeled 869 the log2-transformed expression data as a function of additive genotype effect, controlling for the top 10 expression PCs per summary type and the first 3 ancestry MDS components from 870 the genetic data. We lastly used the allele information to ensure additive effects across study 871 were relative to the same allele, flipping the directionality of such effects where the major allele 872 in one study corresponded to the minor allele in the other study. The eQTLs that were 873 directionality consistent (same allelic directionality of the additive effect on expression) and had 874 875 marginal significance (p<0.01) were considered replicated and retained for summarization.

GTEx: we performed analogous replication analyses as described above across the 1184 GTEx
 brain samples that had genotype and RNA-seq data. While we calculated eQTL replication
 statistics separately by brain region, we adjusted for the first 10 expression PCs from the entire
 sample (across all brain regions), as well as MDS ancestry components from across the

genome. We only considered eQTLs from the frontal cortex brain region for replication,

- 881 enforcing directional consistency as the data set was much smaller than both our discovery and
- first replication dataset (N=99).

After computing replication statistics in the CMC and GTEx frontal cortex datasets, the eQTLs

- that were directionality consistent (same allelic directionality of the additive effect on expression)
- in both datasets and had marginal significance (p<0.01) in CommonMind were considered
- replicated and retained for summarization (see Table S9). Factors positively influencing
- replication were, as expected, the statistical magnitude of the eQTL effect (absolute T-statistic),
- the minor allele frequency, and the mean expression level.
- 889
- 890

891 <u>Clinical enrichment analyses:</u>

892 We first calculated the "risk" effects of the schizophrenia GWAS variants using the set of all

893 GWAS results from: https://www.med.unc.edu/pgc/files/resultfiles/scz2.snp.results.txt.gz and

identified which allele at each SNP corresponded to increased risk, e.g. a positive odds ratio.

895 We then used these risk alleles to convert the directionality of our eQTL effects to reflect the

- reference allele being the risk allele (rather than the minor allele). Lastly, we incorporated the
- qSV-adjusted case-control fold changes to identify the genetic and clinical directional consistent
- 898 features. Enrichment analyses for fetal effects, isoform shift genes, and directional consistency
- 899 was performed using Chi-squared tests with 1 df using the `chisq.test()` in R.
- 900

901 References

- 2 Ripke, S. *et al.* Biological insights from 108 schizophrenia-associated genetic loci.
- 903 *Nature* **511**, 421-+, doi:10.1038/nature13595 (2014).
- 9044Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from905RNA-seq reads. Nature biotechnology 33, 290-295, doi:10.1038/nbt.3122 (2015).
- 6 Collado Torres, L. *et al.* Flexible expressed region analysis for RNA-seq with derfinder.
 907 *Nucleic Acids Research* In Press., doi:10.1101/015370 (2016).
- 9087Jaffe, A. E. *et al.* Developmental regulation of human cortex transcription and its clinical909relevance at single base resolution. Nat Neurosci 18, 154-161, doi:10.1038/nn.3898910(2015).
- 91115Jaffe, A. E. *et al.* A framework for RNA quality correction in differential expression912analysis. *bioRxiv*, doi:10.1101/074245 (2016).
- Lipska, B. K. *et al.* Critical factors in gene expression in postmortem human brain: Focus
 on studies in schizophrenia. *Biol Psychiatry* **60**, 650-658,
- 915 doi:10.1016/j.biopsych.2006.06.019 (2006).
- 816 24 Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of
 917 insertions, deletions and gene fusions. *Genome Biol* 14, R36, doi:10.1186/gb-2013-14-4918 r36 (2013).

- 25 919 Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for 920 assigning sequence reads to genomic features. *Bioinformatics* **30**, 923-930, doi:10.1093/bioinformatics/btt656 (2014). 921 922 26 regtools v. 0.1.0 (2016). Trapnell, C. et al. Transcript assembly and quantification by RNA-Seg reveals 923 27 unannotated transcripts and isoform switching during cell differentiation. Nature 924 925 biotechnology 28, 511-515, doi:10.1038/nbt.1621 (2010). 926 28 Frazee, A. C. et al. Ballgown bridges the gap between transcriptome assembly and 927 expression analysis. Nature biotechnology 33, 243-246, doi:10.1038/nbt.3172 (2015). 29 928 Scharpf, R. B., Irizarry, R. A., Ritchie, M. E., Carvalho, B. & Ruczinski, I. Using the R 929 Package crimm for Genotyping and Copy Number Estimation. J Stat Softw 40, 1-32 930 (2011). 931 30 Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype imputation 932 method for the next generation of genome-wide association studies. PLoS genetics 5, 933 e1000529, doi:10.1371/journal.pgen.1000529 (2009). 934 31 Delaneau, O., Coulonges, C. & Zagury, J. F. Shape-IT: new rapid and accurate algorithm for haplotype inference. BMC bioinformatics 9, 540, doi:10.1186/1471-2105-9-935 936 540 (2008). 32 937 Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based 938 linkage analyses. American journal of human genetics 81, 559-575, doi:10.1086/519795 939 (2007).Buja, A. & Eyuboglu, N. Remarks on Parallel Analysis. Multivariate Behavioral Research 940 33 941 27, 509-540, doi:10.1207/s15327906mbr2704_2 (1992). 34 Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E. & Storey, J. D. The sva package 942 943 for removing batch effects and other unwanted variation in high-throughput experiments. 944 Bioinformatics 28, 882-883, doi:10.1093/bioinformatics/bts034 (2012). 945 35 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing 946 biological themes among gene clusters. Omics : a journal of integrative biology 16, 284-947 287, doi:10.1089/omi.2011.0118 (2012). Smyth, G. K. Linear models and empirical Bayes methods for assessing differential 948 36 949 expression in microarray experiments. Statistical applications in genetics and molecular 950 *biology* **3**, Article 3 (2004). 951 37 Shabalin, A. A. Matrix eQTL: ultra fast eQTL analysis via large matrix operations. 952 Bioinformatics 28, 1353-1358, doi:10.1093/bioinformatics/bts163 (2012). 953
- Author information: sequencing reads and genotype data are available through SRA and
 dbGaP at accession numbers: [TBD]. Reprints and permissions information is available
 at <u>www.nature.com/reprints</u>. Correspondence and requests for materials should be addressed
 to Andrew Jaffe (andrew.jaffe@libd.org). The following authors have competing interests:
- 958 Tony Kam-Thong is employed by F. Hoffmann-La Roche
- 959 Hualin S Xi and Jie Quan are employees of Pfizer Inc.
- Alan Cross, and Nicholas J.Brandon were full time employees and shareholders in AstraZeneca at the time these studies were conducted.
- 962 The remaining authors declare no competing financial interests.

963

964 Supplementary Information

965 Supplementary Figure Legends:

Figure S1: Study overview and cartoon describing quantifying the five different expressionsummarizations.

Figure S2: Cartoon describing the four different splice junction annotation classes, relative to
annotated exons (dark blue rectangles). (A) Annotated splice junctions map between two exons
in a known transcript. (B) Exon-skipping splice junctions map to two annotated exons in different
transcripts. (C) Alternative start/exon junctions map to only one annotated exon on either the 5'
or 3' end. (D) Completely novel junction do not map to any known exon.

Figure S3: Venn diagram of developmentally regulated features mapped back to Ensembl

Gene IDs by the five feature summarization methods. DER: differentially expressed region.

Figure S4: Venn diagram of Ensembl Gene IDs that contain significant isoform shifts by the four
 feature summarization methods that allow for multiple features per gene. DER: differentially
 expressed region.

Figure S5: Degradation quality (DEqual) plots for diagnosis-associated differential expression
analyses at the gene level. Y-axis: T-statistic for the effect of RNA degradation on each gene, Xaxis: diagnosis T-statistic, adjusting for (left) nothing/univariate effect, (middle) observed clinical

981 and technical confounders and (right) the inclusion of the quality surrogate variables.

982 **Figure S6**: Replication rates for three differential expression statistical models. X-axis:

discovery p-value, Y-axis: replication rate, e.g. the proportion of features that have directional
 consistency and are marginally significant (at p<0.05) in independent data. Point size is

proportion to the number of features called significant at the indicated p-value threshold.

Figure S7: Scatter plot of effect sizes (fold changes) in discovery and replication datasets for
 those features significant and replicated. Colors have the same legend as Figure 3A.

Figure S8: GWAS loci set-level analysis for (A) all features together and then stratified by only

(B) genes, (C) exons, (D) junctions, (E) transcripts and (F) expressed regions. P-values were
 based on the Wilcoxon rank sign test.

Figure S9: Boxplots of single gene eQTL effects for GWAS associated SNPs for theassociations not featured in Figure 4.


993


994 Supplementary Table Legends:

Table S1: Demographic information for subjects in the present study, stratified by age and
diagnosis group. Dx: diagnosis, N: sample size, F: Female, Cauc: Caucasian, SD: standard
deviation, PCW: post-conception weeks. Antipsychotic use was measured using toxicology at


- time of death. P-values for diagnosis differences in continuous variables are based on linear
 regression and P-values for categorical variables are based on chi-squared tests.
- 1000 **Table S2**: Splice junction annotation and characterization in GTEx and GEUVADIS for any
- junction or highly expressed junctions (mean reads per 80M mapped reads, RP80M > 0 and 5).
- 1002 Each column represents a 2x2 table for presence of identified junctions in 495 DLPFC samples
- 1003 in two independent polyA+ datasets. This table is analogous to Table 1.
- **Table S3**: Summary statistics for those features significantly developmentally regulated in thecontrol-only analyses across the lifespan.
- **Table S4**: Significant developmentally regulated features collapsed to Ensembl Gene ID, usedto make Figure S3
- 1008 **Table S5**: Isoform shifts by Ensembl Gene ID and feature summarization type.
- **Table S6**: Gene set analyses for those genes with significant isoform shift, stratified by feature
 summarization type. Q-values, which control the false discovery rate, FDR, are shown.
- 1011 **Table S7**: Genes within the PGC schizophrenia GWAS risk regions that contain isoform shifts
- by feature summarization type. 21.8% of PGC2 genes had developmental isoform shifts using exon counts (N=96/440) and 31.9% showed this isoform shift association based on junction counts (N=137/430)
- **Table S8**: eQTL replication metrics for CommonMind Consortium, GTEx frontal cortex, and both
 among all significant eQTLs in the discovery adult sample.
- **Table S9**: eQTL statistics for the best SNP-feature pair in the discovery sample that replicatedin CMC and GTEx frontal cortex, by feature type.
- **Table S10**: Differential expression statistics for those features that were significant andreplicated in case-control comparisons.
- **Table S11**: Genes consistently differentially expressed by case-control analysis for the differentfeature summarizations.
- Table S12: Associations between diagnosis, RPS and expression at gene and exon levels. First
 two columns for each feature: p-values for gene set tests for the significant case-control
 features among statistics capturing the effect of RPS on expression. Second two columns for
 each feature: directionality between RPS on expression associations and diagnosis on
 expression associations.
- **Table S13**: Gene set analysis for genes with features differentially expressed by case-control
 status, stratified by directionality and feature summarization type.
- **Table S14**: GWAS region set-level analyses for diagnosis-associated differentially expressed
 features, testing whether features in the PGC risk loci were more or less expressed as a set in


- 1032 cases compared to controls. Qual: qSVA adjusted analysis, Adj: observed covariate adjusted1033 analysis.
- **Table S15**: eQTL statistics for all PGC SCZD GWAS variants, including the risk direction (eQTL
 and GWAS) and clinical direction (case-control fold change)
- 1036 **Table S16**: eQTL statistics filtered to those that were directionally consistent between risk and clinical directionalities
- **Table S17**: Analogous to Table 2 with Ensembl transcript annotation data to highlight transcriptspecificity.
- 1040







А	Gene	Exon	Transcript	Junction	DERs
# Bonf < 0.05	4934	36299	2993	5683	20295
p-value cutoff	8.39E-09	7.64E-10	1.71E-09	1.09E-09	1.28E-09
# Ens Genes	4934	6698	1708	2588	5381
# Sym Genes	3675	5195	1701	2376	4503
Effect Size	1.07	1.15	1.1	1.36	1.25
Median (IQR)	(1.04-1.11)	(1.1-1.23)	(1.05-1.2)	(1.19-1.63)	(1.16-1.42)
Distance	-40bp	-27bp	-130bp	-23bp	-23bp
Median (IQR)	(-9.4kb-9.4kb)	(-14kb-13kb)	(-7.8kb-5.9kb)	(-10kb-8.8kb)	(-13kb-12kb)
% Novel	NA	NA	37.5%	11.3%	52.7%
% Isoform- specific	NA	67.0%	100%	31.1%	NA







Distance: SNP to Feature (kb)



Supplementary Results for: Developmental and genetic regulation of the human frontal cortex transcriptome in schizophrenia

Andrew E Jaffe, Richard E Straub, Joo Heon Shin, Ran Tao, Yuan Gao, Leonardo Collado Torres, Tony Kam-Thong, Hualin S Xi, Jie Quan, Carlo Colantuoni, Qiang Chen, Bill Ulrich, Brady J. Maher, Amy Deep-Soboslay, The BrainSeq Consortium, Alan Cross, Nicholas J. Brandon, Jeffrey T Leek, Thomas M. Hyde, Joel E. Kleinman, Daniel R Weinberger

1. Deep characterization of the human cortex transcriptome

We used Ensembl v75 annotation to quantify the normalized expression (via reads per kilobase per million reads mapped. RPKM) of 615.410 exons across 63.677 genes, and guided transcript assembly within and across samples to identify and quantify 188,578 transcripts with at least modest expression across all of the samples¹. Only approximately half of the assembled transcripts were found in Ensembl annotation (N=100,932, 53.5%), while 41.8% (N=78,751) consisted of transcripts with novel splicing patterns. We also more directly interrogated the spliced alignments, which supported 3,582,199 unique exon-exon splice junctions across the 495 samples. We defined four classes of splice junctions based on the Ensembl gene/transcript annotation - present/existing, exon skipping, alternative exonic boundary, and completely novel (Figure S2, Table S2), and found moderate expression of many potentially unannotated transcripts in brain. To assess the replication and brain specificity of our findings, we identified junctions in both the brain samples from the GTEx project (N=1,393 samples from 201 individuals) and lymphoblastoid cell lines (LCLs) from the GEUVADIS project (N=666, see Methods). Overall, we find extensive replication in human brain GTEx samples of annotated junctions (95.0%), and high replication of potentially novel transcripts that capture exon skipping (75.6%) or alternative exonic boundaries (65.8%), with extremely high replication (>95%, Table 1). Much of this novel transcriptional activity appeared relatively-brain specific, as few junctions identified in DLPFC were present only in GEUVADIS LCLs and not GTEx brain samples further suggesting that this degree of junction discovery was not largely driven by alignment software. We lastly defined "expressed regions" (ERs) of contiguously expressed sequence - these ERs and junctions together can "tag" elements of transcripts in the data that are not constrained by limitations or incompleteness of existing annotation.

2. Developmental regulation of human brain transcription

We sought in this study to more fully characterize developmental regulation of transcription across human brain development and aging, and modeled dynamic expression in 320 control samples using flexible linear splines in each of the five expression summarizations (see Methods). We found widespread developmental regulation across all five features(Table S3) corresponding to 30,490 unique Ensembl genes (across 20,596 gene symbols), including a core set of 15,603 genes with all five features showing convergent expression association with

development/aging (Figure S3). There were 89,865 previously unannotated expressed features corresponding to the majority of genes (17,374 IDs and 15,261 symbols) with genome-wide significant dynamic expression across brain development in these unaffected subjects (Table S4). The majority of these unannotated features were identified using the splice junction counts (N=43,512, 48.4%) of which 31,183 junctions (71.7%) tagged alternative exonic boundaries and 12,329 junctions (28.3%) corresponding to exonic skipping, while there were 26,010 differentially expressed regions (DERs, 28.9%) that all correspond to alternative exonic boundaries and 20,343 transcripts of which 19,138 (94.1%) correspond to exonic skipping.

3. Expression associations with chronic schizophrenia illness

Given the apparent lower RNA quality of patient samples in virtually all schizophrenia brain case control studies including our own (see Table S1), we filtered the 384 samples above age 17 (209 controls and 175 patients) to a subset of 351 higher quality samples (196 controls and 155 cases) using metrics of age, ancestry, RNA quality, and cryptic ancestry (see Methods). Even after filtering, using gene-level expression, univariate comparisons between SCZD patients and controls identified 12,686 genes differentially expressed (DE) at a false discovery rate (FDR) < 5%, suggesting a large degree of bias. Regression modeling, adjusting for age, sex, ancestry, and observed RNA quality (see Methods) reduced the extent of confounding, resulting in 1,988 genes DE between patients and controls at FDR < 5%. We identified the largest number of significant and replicated DE features using exon counts (N=274) followed by gene counts (N=170) and expressed region counts (N=110). Very few DE junctions (N=2) and no DE transcripts were identified and independently replicated, which likely highlight the decreased statistical power using these approaches when annotated features are differentially expressed (see Discussion). Approximately one half of the genes annotated by these DE features were identified using gene-level summarization only (86/170, 50.6%), which utilize the largest number of reads collapsed across all possible transcript isoforms (Table S11). The majority of genes with DE signal were only supported by a single summarization type across both Ensembl IDs (142/237, 59.9%) and gene symbols (119/209 56.9%, Table S11).

Interestingly, analogous analyses for developmental regulation of schizophrenia-associated features without adjusting for the RNA quality qSVs were significant in the opposite directions, namely that schizophrenia-associated changes were further from, rather than closer to, fetal expression levels, which would be predicted as an effect of residual RNA quality confounding (as the quality of the samples were ranked fetal > adult control > adult SZ, see Table S1). This directional difference in RNA quality between fetal and postnatal samples is also typical of earlier studies (e.g. Colantuoni, Geschwind, etc).

4. GWAS implications of illness-associated expression differences

Only two genes in the 108 significant schizophrenia GWAS loci (KLC1 and PPP2R3A) had expression features significantly differentially expressed and replicated. To potentially identify more subtle associations within these GWAS risk regions, we performed an exploratory "feature set" analysis (analogous to traditional gene set analyses) comparing the schizophrenia differential expression statistics of all expressed features within the loci to those outside the loci. We found decreased expression of the 15,050 expressed features within the risk loci in patients compared to controls, relative to the 996,775 expressed features outside of the loci, adjusting for mean expression level (Figure S8A, $p = 3.32 \times 10^{-36}$, Table S13). While the absolute set-level effect sizes were small, these GWAS region-level associations were largely consistent when stratified by summarization type, with the exception of transcript counts which showed no association. Of particular importance is the observation that these findings also were only significant after quality adjustment in the differential expression analysis (Figures S8B-F) analyses adjusting for only the usual observed confounders (e.g. clinical covariates and observed quality variable) showed no enrichment among PGC risk regions (p=0.2, Table S13). Therefore, while many of the case-control expression differences that meet both genome-wide statistical significance and replication criteria may be related to schizophrenia treatment and epiphenomena and depleted for GWAS regions, some differences in expression in some subsets of patient populations might be related to genetic risk for the disorder, though the biological interpretation of the feature distribution differences is not clear. Larger studies can likely improve power to detect expression changes within the GWAS risk regions amidst the clinical and molecular heterogeneity of schizophrenia.

5. Genetic control of RNA expression levels in the cortex

In order to elucidate the RNA features associated with schizophrenia risk variants themselves, rather than LD regions, we first performed a *cis* (<500kb) genome-wide expression quantitative trait loci (eQTL) analysis across the five expression feature summarizations. These analyses were performed within the post-adolescent subjects, including both cases and controls (age > 13, N=412) across densely observed and imputed common and high-quality SNP genotypes (MAF > 5%, N=7,421,423), adjusting for components related to ancestry and expression heterogeneity in each feature type (see Methods). Given the large number of tests, but also the need for comparability across the five expression summarizations, we adjusted for multiple testing using both the false discovery rate (FDR) with a cutoff of 1%, in line with the GTEX project ² and also a more stringent Bonferroni-based cutoff adjusting for the number of LD-independent SNP-feature pairs. These multiple testing thresholds corresponded to $p<1.0x10^{-4}$ and $p<2.6x10^{-9}$, respectively, across the 5 feature summarizations.

We examined only eQTL associations of 682,828 unique genetic variants to a total of 70,204 nearby expression features, mapping back to 9,271 Ensembl IDs (of which 7,057 had HGNC symbols) that were at Bonferroni significance in our dataset and that replicated in the two independent datasets (Figure 3A, Table S10). We highlight the best SNP for each feature in Table S11, and have a complete database, including statistics and visualizations, of all significant and replicated eQTLs online (as well as significant control-only eQTLs) via a user

friendly browser at <u>http://eqtl.brainseq.org</u>. The majority of eQTLs (N=417,276, 61.1%) associated with features in a single Ensembl gene, and another large subset associated with features in two nearby genes (N=133,286, 19.5%). Conversely, the majority of genes were associated with more than 1 LD-independent SNP (76.3%) across the feature summarizations, including approximately half (49.0%) of genes having features associated with more than 3 LD-independent SNPs, suggesting that multiple variants can associate with expression independently of each other, and potentially result in more normally-distributed expression levels at the population-level. Furthermore, the eQTL effects (discovered in multiple/mixed ancestries) were largely consistent between Caucasian and African American subjects (Figure 2B). The most significant SNP for each eQTL feature was extremely proximal to the feature (based on nearest coordinate), with a median < 50bp (IQR less than -15kb to 15kb, Figure 2C). Lastly, we found the largest effect sizes on average for the junction and ER eQTLs (see Supplementary Results, Figure 2D).

While the majority of genes with features as eQTLs have multiple possible Ensembl isoforms, 67.0% of exon eQTLs and 31.1% of junction eQTLs were specific to a single Ensembl transcript when multiple transcripts existed for a given gene. Furthermore, 640 (11.2%), 1,123 (37.5%) and 10,698 (52.7%) of replicated junction, transcript, and expressed region eQTLs respectively, corresponded to novel transcriptional activity, including 387 alternative exonic boundary and 253 exon-skipping junction eQTLs and 4,036 alternative exonic boundary (crossing an intron and exon, and extended UTRs) and 6,662 intronic and intergenic ERs. These results indicate that performing both exon- and junction-level eQTL analyses together provide an encompassing view of genetic regulation of expression, as exon-level analyses identified eQTLs for the most genes as well as transcript-specific events, and junction-level analysis provided the largest biological effect sizes and the ability to identify potentially novel transcript isoforms. Together these eQTL results, based on analyses across multiple feature summarizations from RNA sequencing data, demonstrate more widespread genetic regulation of expression than previously reported, including extensive transcript specificity and regulation of unannotated sequence in the human brain.

There was moderate concordance across the different feature summarizations. Exonlevel summarizations resulted in the largest number of unique genes as eQTLs (N=6,698) and transcript-level summarizations resulted in the fewest (N=1,708). While the junction eQTLs were less likely to appear in the GTEX project likely because of the lower coverage, and therefore replicate, those that did replicate tended to have larger effect sizes than other summarizations, with a median 36% (IQR: 19-63%) change in expression per allele copy (Figure 2D). Expressed region-level analysis identified the second most eQTLs to unique genes (N=5,381) and effect sizes (median: 25%, IQR: 16-42%). Gene-level eQTL analysis, which is the de-facto approach in RNA-seq analysis, resulted in the smallest eQTL effects, with a 7% (IQR: 4-11%) change in expression per allele copy, and identified fewer unique genes than exon and expressed region analysis (N=4,934). These data suggest that most eQTLs involve specific transcript isoforms whose signals may be diluted when examining only gene-level expression data. If this dilution when using gene counts results from averaging over potentially transcript-specific eQTLs, then mapping all expressed features (sans expressed regions) to all known Ensembl transcripts, and tabulating the proportion of eQTLs that appear relatively transcript specific should confirm this. In fact, there was extensive evidence of transcript-specificity of replicated eQTLs across exons, junctions, and transcripts.

6. Characterization of schizophrenia risk-associated expressed features

We found significant enrichment of this directional consistency between the GWAS, casecontrol, and FDR-significant (34 loci across 444 eQTL features and 91 Ensembl genes, OR=2.00, $p=4.2x10^{-6}$) as well as with the more conservative Bonferroni-significant (19 loci across 161 features and 44 Ensembl genes, OR=4.67, $p=7.97x10^{-8}$) features

The majority of our eQTLs (SNP-feature pairs) had directionally consistent allelic effects in the 50 fetal samples (N=628, 82.2%, p < 10^{-20}) and a subset were marginally significant (at p < 0.05) even in this small sample size (N=162, 21.2%). As further evidence for similar genetic regulation, every eQTL that was marginally significant in the fetal samples was directionally consistent with the eQTL effect in the adult samples. For example, we find the most significant and replicated association with clinical directional consistency between rs4523957 (PGC rank 47) and exons (as well as other feature types, see Table S15) in Serine Racemase (*SRR*, Figure 4B), an NMDAR modulator previously associated with schizophrenia³. While the statistical significance of exon associations were only slightly better than at the gene level (2.1×10^{-12} versus 5.44x10⁻¹¹), the effect size was almost three times larger (-0.16 versus -0.06). Similarly we identified significant eQTL association between rs324017 (PGC rank 103), and exon- and junction-level expression of *STAT6* (Figure 4C), a transcription factor involved in interleukin signaling⁴ whereas there were no significant and replicated eQTLs at the gene-level.

The approach that was unconstrained by annotation also identified novel associations to schizophrenia risk, for example, the eQTL of rs6434928 (PGC rank 33) with intronic sequence in the *HSPD1* and *HSPE1* heat shock protein genes (Figure 4D,E), which are co-chaperonins linked by a common bidirectional promoter⁵. While both genes were recently highlighted in the subset of 20 PGC GWAS genes that are targets of currently approved drugs⁶, the strictly intronic annotation of the eQTL association may suggest a different mechanism of risk from this locus in schizophrenia, and thus a different requirement for a therapeutic agent. Finally, we highlight the eQTL association between rs13240464 (PGC rank 16) and the expression level of a novel splice junction in *IMMP2L* (Figure 4F,G), a gene important in directing mitochondrial proteins to the mitochondria⁷ and that has been previously associated with autism and Tourette Syndrome⁸.

Supplementary Discussion

This proportion of genetic risk variants that are brain eQTLs – 42.5% – far exceeds previous reports using microarray and gene level (count-based) RNA-seq approaches. For example, of the 18 index SNPs labeled as eQTLs in Supplementary Table 4 In the PGC publication ⁹, only 8 risk loci had variants moderately linked (at R² > 0.6) to significant (at p < 10^{-4}) brain eQTLs. Our results highlight the enhanced detection of eQTL signals from GWAS-

positive risk variants using RNA-seq to quantify convergent measures of expression beyond the usual gene-level quantification in large collections of postmortem human brains.

In the original GWAS report, while there were only 18 reported index SNPs with brain eQTLs to a total of 30 genes, many of the reported eQTLs were themselves not GWASsignificant variants, being only weakly linked (at $R^2 < 0.6$) to the best GWAS SNP. There were only three of these 18 GWAS- and eQTL-significant index SNPs (putatively associating with C10orf32 (BORCS7), AS3MT, OGFOD2, NAGA, and CENPM) that were present in our larger RNA-seq data from the three independent studies that we surveyed. Similarly, a recent GWAS and eQTL integration analysis based on peripheral blood eQTLs identified very few overlapping genes¹⁰. These genes included PCCB, SNX19, GATAD2A, and IRF3 as directionally-consistent eQTLs (with regard to the GWAS, eQTL, and case-control differences described above), and SF3B1 and PSMA4 as non-directionally consistent eQTLs, suggesting the need to guery the disease-relevant tissue, i.e. human brain. Interrogating annotation-agnostic expression features added a considerable number of loci with eQTL signal further highlighting the value of RNA sequencing-based datasets. For example, we have recently dissected the GWAS signal in the 10g24.32 region in a more focused analysis based on the expression features highlighted in the current report. There we identified based on junction-level analysis a novel risk-associated isoform of AS3MT that is missing exons 2 and 3¹¹. This analysis showed that the previously referenced genetic association with this locus to AS3MT was inaccurate, as no association was found to the full length AS3MT¹¹, and importantly, the novel isoform does not have arsenic methyltransferase activity. Furthermore, eight additional loci, with clinical risk variants associating with expression of SNX19, NRGN/VSIG2, HSPD1, GATAD2A/NDUGA13, VPS45, GPM6A, SOX2-OT, and BRINP2, were identified here (and subsequently replicated) only via junction- and expressed region-level analysis.

References

- 1 Frazee, A. C. *et al.* Ballgown bridges the gap between transcriptome assembly and expression analysis. *Nature biotechnology* **33**, 243-246, doi:10.1038/nbt.3172 (2015).
- 2 Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. *Science* **348**, 648-660, doi:10.1126/science.1262110 (2015).
- 3 Labrie, V. *et al.* Serine racemase is associated with schizophrenia susceptibility in humans and in a mouse model. *Human molecular genetics* **18**, 3227-3243, doi:10.1093/hmg/ddp261 (2009).
- 4 Shimoda, K. *et al.* Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. *Nature* **380**, 630-633, doi:10.1038/380630a0 (1996).
- 5 Ryan, M. T. *et al.* The genes encoding mammalian chaperonin 60 and chaperonin 10 are linked head-to-head and share a bidirectional promoter. *Gene* **196**, 9-17 (1997).
- 6 Lencz, T. & Malhotra, A. K. Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic. *Molecular psychiatry* **20**, 820-826, doi:10.1038/mp.2015.28 (2015).
- 7 Nunnari, J., Fox, T. D. & Walter, P. A mitochondrial protease with two catalytic subunits of nonoverlapping specificities. *Science* **262**, 1997-2004 (1993).
- 8 Petek, E. *et al.* Molecular and genomic studies of IMMP2L and mutation screening in autism and Tourette syndrome. *Molecular genetics and genomics : MGG* **277**, 71-81, doi:10.1007/s00438-006-0173-1 (2007).

- 9 Ripke, S. *et al.* Biological insights from 108 schizophrenia-associated genetic loci. *Nature* **511**, 421-+, doi:10.1038/nature13595 (2014).
- 10 Zhu, Z. *et al.* Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. *Nature genetics* **48**, 481-487, doi:10.1038/ng.3538 (2016).
- 11 Li, M. *et al.* A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus. *Nature medicine*, doi:10.1038/nm.4096 (2016).